Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1147MR)

This product GTTS-WQ1147MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers, non-small cell lung (NSCLC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1147MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9161MR IVTScrip™ mRNA-Anti-CD37, IMGN-529(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IMGN-529
GTTS-WQ13408MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ7980MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GX-H9
GTTS-WQ328MR IVTScrip™ mRNA-Anti-CD27, 1F5(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 1F5
GTTS-WQ1208MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ6630MR IVTScrip™ mRNA-Anti-CD79B, DCDS0780A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA DCDS0780A
GTTS-WQ11432MR IVTScrip™ mRNA-Anti-F, MEDI-8897(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MEDI-8897
GTTS-WQ11954MR IVTScrip™ mRNA-Anti-LTA, MLTA3698A(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MLTA3698A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW